Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 Apr;23(4):593–597. doi: 10.1128/aac.23.4.593

Effect of several antiviral agents on human lymphocyte functions and marrow progenitor cell proliferation.

J R Wingard, A D Hess, R K Stuart, R Saral, W H Burns
PMCID: PMC184707  PMID: 6305264

Abstract

Toxicity to hematopoiesis and lymphocytic function are major considerations in the clinical applicability of antiviral agents. We have examined the toxicities of five antiviral agents showing activity against herpesviruses: vidarabine, acyclovir, (E)-5-(2-bromovinyl)-2'-deoxyuridine, trifluorothymidine, and (S)-9-(2,3-dihydroxypropyl)adenine. The drugs were tested in vitro for inhibition of herpes simplex virus type 1 and human cytomegalovirus replication, effects on marrow progenitor cell growth, effects on lymphocyte responses to mitogen and alloantigen stimulation, and effects on several lymphocyte cytotoxic responses. In general, lymphocyte proliferative responses were inhibited by the various drugs at lower concentrations than were cytotoxic activities. Acyclovir and (E)-5-(2-bromovinyl)-2'-deoxyuridine were the least toxic drugs tested, with antiviral indices exceeding 10,000. Vidarabine and trifluorothymidine were more toxic, with antiviral indices generally between 10 and 100. (S)-9-(2,3-dihydroxypropyl)-adenine was the most toxic, with several antiviral indices between 1 and 10.

Full text

PDF
593

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biron K. K., Elion G. B. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother. 1980 Sep;18(3):443–447. doi: 10.1128/aac.18.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Burns W. H., Wingard J. R., Bender W. J., Saral R. Thymidine kinase not required for antiviral activity of acyclovir against mouse cytomegalovirus. J Virol. 1981 Sep;39(3):889–893. doi: 10.1128/jvi.39.3.889-893.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Crumpacker C. S., Schnipper L. E., Zaia J. A., Levin M. J. Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother. 1979 May;15(5):642–645. doi: 10.1128/aac.15.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DE Clercq E., Descamps J., DE Somer P., Holyacute A. (S)-9-(2,3-Dihydroxypropyl)adenine: An Aliphatic Nucleoside Analog with Broad-Spectrum Antiviral Activity. Science. 1978 May 5;200(4341):563–565. doi: 10.1126/science.200.4341.563. [DOI] [PubMed] [Google Scholar]
  5. De Clercq E., Descamps J., De Somer P., Barr P. J., Jones A. S., Walker R. T. (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2947–2951. doi: 10.1073/pnas.76.6.2947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716–5720. doi: 10.1073/pnas.74.12.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hess A. D., Tutschka P. J. Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR. J Immunol. 1980 Jun;124(6):2601–2608. [PubMed] [Google Scholar]
  8. KAUFMAN H. E., HEIDELBERGER C. THERAPEUTIC ANTIVIRAL ACTION OF 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE IN HERPES SIMPLEX KERATITIS. Science. 1964 Aug 7;145(3632):585–586. doi: 10.1126/science.145.3632.585. [DOI] [PubMed] [Google Scholar]
  9. Keeney R. E., Kirk L. E., Bridgen D. Acyclovir tolerance in humans. Am J Med. 1982 Jul 20;73(1A):176–181. doi: 10.1016/0002-9343(82)90086-9. [DOI] [PubMed] [Google Scholar]
  10. Kraemer K. G., Neiman P. E., Reeves W. C., Thomas E. D. Prophylactic adenine arabinoside following marrow transplantation. Transplant Proc. 1978 Mar;10(1):237–240. [PubMed] [Google Scholar]
  11. Levin M. J., Leary P. L., Arbeit R. D. Effect of acyclovir on the proliferation of human fibroblasts and peripheral blood mononuclear cells. Antimicrob Agents Chemother. 1980 Jun;17(6):947–953. doi: 10.1128/aac.17.6.947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. McGuffin R. W., Shiota F. M., Meyers J. D. Lack of toxicity of acyclovir to granulocyte progenitor cells in vitro. Antimicrob Agents Chemother. 1980 Sep;18(3):471–473. doi: 10.1128/aac.18.3.471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ortaldo J. R., Bonnard G. D., Kind P. D., Herberman R. B. Cytotoxicity by cultured human lymphocytes: characteristics of effector cells and specificity of cytotoxicity. J Immunol. 1979 Apr;122(4):1489–1494. [PubMed] [Google Scholar]
  14. Parker L. M., Lipton J. M., Binder N., Crawford E. L., Kudisch M., Levin M. J. Effect of acyclovir and interferon on human hematopoietic progenitor cells. Antimicrob Agents Chemother. 1982 Jan;21(1):146–150. doi: 10.1128/aac.21.1.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Parkman R., Gelfand E. W., Rosen F. S., Sanderson A., Hirschhorn R. Severe combined immunodeficiency and adenosine deaminase deficiency. N Engl J Med. 1975 Apr 3;292(14):714–719. doi: 10.1056/NEJM197504032921402. [DOI] [PubMed] [Google Scholar]
  16. Quinnan G. V., Jr, Kirmani N., Esber E., Saral R., Manischewitz J. F., Rogers J. L., Rook A. H., Santos G. W., Burns W. H. HLA-restricted cytotoxic T lymphocyte and nonthymic cytotoxic lymphocyte responses to cytomegalovirus infection of bone marrow transplant recipients. J Immunol. 1981 May;126(5):2036–2041. [PubMed] [Google Scholar]
  17. Quinnan G. V., Jr, Kirmani N., Rook A. H., Manischewitz J. F., Jackson L., Moreschi G., Santos G. W., Saral R., Burns W. H. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med. 1982 Jul 1;307(1):7–13. doi: 10.1056/NEJM198207013070102. [DOI] [PubMed] [Google Scholar]
  18. Saral R., Burns W. H., Laskin O. L., Santos G. W., Lietman P. S. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med. 1981 Jul 9;305(2):63–67. doi: 10.1056/NEJM198107093050202. [DOI] [PubMed] [Google Scholar]
  19. Schaeffer H. J., Beauchamp L., de Miranda P., Elion G. B., Bauer D. J., Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature. 1978 Apr 13;272(5654):583–585. doi: 10.1038/272583a0. [DOI] [PubMed] [Google Scholar]
  20. Steele R. W., Keeney R. E., Brown J., 3rd, Young E. J. Cellular immune responses to herpesviruses during treatment with adenine arabinoside. J Infect Dis. 1977 Apr;135(4):593–599. doi: 10.1093/infdis/135.4.593. [DOI] [PubMed] [Google Scholar]
  21. Steele R. W., Marmer D. J., Keeney R. E. Comparative in vitro imunotoxicology of acyclovir and other antiviral agents. Infect Immun. 1980 Jun;28(3):957–962. doi: 10.1128/iai.28.3.957-962.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stevens D. A., Jordan G. W., Waddell T. F., Merigan T. C. Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med. 1973 Oct 25;289(17):873–878. doi: 10.1056/NEJM197310252891701. [DOI] [PubMed] [Google Scholar]
  23. Tedde A., Balis M. E., Ikehara S., Pahwa R., Good R. A., Trotta P. P. Animal model for immune dysfunction associated with adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1980 Aug;77(8):4899–4903. doi: 10.1073/pnas.77.8.4899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tone H., Heidelberger C. Fluorinated pyrimidines. XLIV. Interaction of 5-trifluoromethyl-2'-deoxyuridine 5'-triphosphate with deoxyribonucleic acid polymerases. Mol Pharmacol. 1973 Nov;9(6):783–791. [PubMed] [Google Scholar]
  25. Whitley R. J., Ch'ien L. T., Dolin R., Galasso G. J., Alford C. A., Jr Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N Engl J Med. 1976 May 27;294(22):1193–1199. doi: 10.1056/NEJM197605272942201. [DOI] [PubMed] [Google Scholar]
  26. Wingard J. R., Stuart R. K., Saral R., Burns W. H. Activity of trifluorothymidine against cytomegalovirus. Antimicrob Agents Chemother. 1981 Sep;20(3):286–290. doi: 10.1128/aac.20.3.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. de Clercq E., Degreef H., Wildiers J., de Jonge G., Drochmans A., Descamps J., de Somer P. Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster. Br Med J. 1980 Nov 1;281(6249):1178–1178. doi: 10.1136/bmj.281.6249.1178. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES